Characterisation of acquired mechanisms of resistance to PARP inhibitors
Annals of Oncology shared a post on X:
“In Annals of Oncology, a Letter to the Editor by Daniel Stover on the characterisation of acquired mechanisms of resistance to PARP inhibitors using serial ctDNA analyses.
Molecular profiling of longitudinal plasma samples characterizes mechanisms of resistance to PARPi in MBC with BRCA1, BRCA2 or PALB2 mutations:
- BRCA1/2 reversion mutations were most prevalent
- LOF mutations in TP53BP1, RIF1 or PAXIP1 less frequent”
Source: Annals of Oncology/X
Dr. Daniel Stover is a medical oncologist specializing in breast cancer treatment at the OSUCCC – James. He also serves as an assistant professor in the Department of Internal Medicine at Ohio State University.
As a member of the Translational Therapeutics Program, his research integrates tumor genomic profiling with patient characteristics and outcomes to develop new treatments for breast cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023